Patents by Inventor Shenjun Li

Shenjun Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CLAUDIN 18.2 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF
    Publication number: 20230272109
    Abstract: Provided are an antibody targeting Claudin 18.2, an antibody-drug conjugate, and use thereof in treatment of cancer. Also provided are a nucleotide encoding the Claudin 18.2 antibody, a polynucleotide combination, an expression vector, an expression vector combination, a pharmaceutical composition comprising the Caudill 18.2 antibody and the antibody-drug conjugate, and an application thereof in preparation of a medication for treatment or prevention of cancer.
    Type: Application
    Filed: May 7, 2022
    Publication date: August 31, 2023
    Inventors: Jianmin FANG, Yuanhao LI, Marie M. ZHU, Jing JIANG, Yuelei SHEN, Shenjun LI, Wenting LUO, Xiaoping ZHANG, Lili WANG, Ling WANG, Qinbin ZHANG, Fang YANG
  • ANTI PD-L1 ANTIBODY AND USE THEREOF
    Publication number: 20220177590
    Abstract: Provided in the present invention is a PD-L1 immunosuppressant, and specifically provided are a monoclonal antibody capable of targeting PD-L1, and nucleotides, combinations of polynucleotides, expression vectors and combinations of expression vectors encoding the antibody. Also provided in the present invention is a conjugate or pharmaceutical composition containing the above-mentioned anti PD-L1 antibody. Further provided in the present invention is the use of the above-mentioned anti PD-L1 antibody, nucleotides, combinations of polynucleotides, expression vectors, combinations of expression vectors, conjugate or pharmaceutical composition in the preparation of a medicament for treating or preventing cancers.
    Type: Application
    Filed: August 25, 2020
    Publication date: June 9, 2022
    Inventors: Jianmin FANG, Jing JIANG, Shenjun LI, Guorui ZHAO
  • ANTI-MESOTHELIN ANTIBODY AND ANTIBODY DRUG CONJUGATE THEREOF
    Publication number: 20220056147
    Abstract: The present invention discloses an antibody drug conjugate that targets MSLN. The present invention also disclosed a method of making the antibody drug conjugate (ADC). The present invention further discloses a novel MSLN antibody or a functional fragment thereof comprising engineered heavy and light chains.
    Type: Application
    Filed: May 15, 2019
    Publication date: February 24, 2022
    Applicant: Remegen, Ltd.
    Inventors: Jianmin Fang, Changjiang Huang, Jing Jiang, Hui Ye, Shenjun Li, Qiaoyu Xu, Wenting Luo, Mingxue Wang
  • APPLICATION OF TACI-FC FUSION PROTEIN IN PREPARATION OF DRUGS FOR TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDERS AND MULTIPLE SCLEROSIS
    Publication number: 20210087253
    Abstract: The present invention relates to the field of B-lymphocyte stimulator receptor-antibody fusion proteins for treating autoimmune diseases, and in particular to a TACI-Fc fusion protein in preparation of drugs for treating neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS).
    Type: Application
    Filed: May 15, 2019
    Publication date: March 25, 2021
    Inventors: Jianmin Fang, Jing Jiang, Shenjun Li, Min Huang
  • Fly fan
    Patent number: D864347
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: October 22, 2019
    Inventor: Shenjun Li